|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase/hydrolase inhibitor
|
 |
|
Title:
|
 |
Crystal and molecular structure of the bovine alpha-chymotrypsin-eglin c complex at 2.0 angstroms resolution
|
|
Structure:
|
 |
Alpha-chymotrypsin. Chain: e. Engineered: yes. Eglin c. Chain: i. Engineered: yes
|
|
Source:
|
 |
Bos taurus. Bovine. Organism_taxid: 9913. Hirudo medicinalis. Medicinal leech. Organism_taxid: 6421
|
|
Biol. unit:
|
 |
Dimer (from
)
|
|
Resolution:
|
 |
|
|
Authors:
|
 |
M.Bolognesi,F.Frigerio,A.Coda,L.Pugliese,C.Lionetti,E.Menegatti, G.Amiconi,H.P.Schnebli,P.Ascenzi
|
|
Key ref:
|
 |
F.Frigerio
et al.
(1992).
Crystal and molecular structure of the bovine alpha-chymotrypsin-eglin c complex at 2.0 A resolution.
J Mol Biol,
225,
107-123.
PubMed id:
|
 |
|
Date:
|
 |
|
08-Nov-91
|
Release date:
|
31-Oct-93
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
Chain E:
E.C.3.4.21.1
- chymotrypsin.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Preferential cleavage: Tyr-|-Xaa, Trp-|-Xaa, Phe-|-Xaa, Leu-|-Xaa.
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
J Mol Biol
225:107-123
(1992)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal and molecular structure of the bovine alpha-chymotrypsin-eglin c complex at 2.0 A resolution.
|
|
F.Frigerio,
A.Coda,
L.Pugliese,
C.Lionetti,
E.Menegatti,
G.Amiconi,
H.P.Schnebli,
P.Ascenzi,
M.Bolognesi.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The crystal structure of the complex between bovine alpha-chymotrypsin and the
leech (Hirudo medicinalis) protein proteinase inhibitor eglin c has been refined
at 2.0 A resolution to a crystallographic R-factor of 0.167. The structure of
the complex includes 2290 protein and 143 solvent atoms. Eglin c is bound to the
cognate enzyme through interactions involving 11 residues of the inhibitor
(sites P5-P4' in the reactive site loop, P10' and P23') and 17 residues from
chymotrypsin. Binding of eglin c to the enzyme causes a contained hinge-bending
movement around residues P4 and P4' of the inhibitor. The tertiary structure of
chymotrypsin is little affected, with the exception of the 10-13 region, where
an ordered structure for the polypeptide chain is observed. The overall binding
mode is consistent with those found in other serine proteinase-protein-inhibitor
complexes, including those from different inhibition families. Contained, but
significant differences are observed in the establishment of intramolecular
hydrogen bonds and polar interactions stabilizing the structure of the intact
inhibitor, if the structure of eglin c in its complex with chymotrypsin is
compared with that of other eglin c-serine proteinase complexes.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
M.J.Whitley,
and
A.L.Lee
(2011).
Exploring the role of structure and dynamics in the function of chymotrypsin inhibitor 2.
|
| |
Proteins,
79,
916-924.
|
 |
|
|
|
|
 |
A.May,
and
M.Zacharias
(2008).
Energy minimization in low-frequency normal modes to efficiently allow for global flexibility during systematic protein-protein docking.
|
| |
Proteins,
70,
794-809.
|
 |
|
|
|
|
 |
N.Rezaei-Ghaleh,
M.Amininasab,
and
M.Nemat-Gorgani
(2008).
Conformational changes of alpha-chymotrypsin in a fibrillation-promoting condition: a molecular dynamics study.
|
| |
Biophys J,
95,
4139-4147.
|
 |
|
|
|
|
 |
B.Y.Chen,
V.Y.Fofanov,
D.H.Bryant,
B.D.Dodson,
D.M.Kristensen,
A.M.Lisewski,
M.Kimmel,
O.Lichtarge,
and
L.E.Kavraki
(2007).
The MASH pipeline for protein function prediction and an algorithm for the geometric refinement of 3D motifs.
|
| |
J Comput Biol,
14,
791-816.
|
 |
|
|
|
|
 |
C.Oliva,
A.Rodríguez,
M.González,
and
W.Yang
(2007).
A quantum mechanics/molecular mechanics study of the reaction mechanism of the hepatitis C virus NS3 protease with the NS5A/5B substrate.
|
| |
Proteins,
66,
444-455.
|
 |
|
|
|
|
 |
M.R.Yun,
N.Mousseau,
and
P.Derreumaux
(2007).
Sampling small-scale and large-scale conformational changes in proteins and molecular complexes.
|
| |
J Chem Phys,
126,
105101.
|
 |
|
|
|
|
 |
J.S.Fetrow,
S.T.Knutson,
and
M.H.Edgell
(2006).
Mutations in alpha-helical solvent-exposed sites of eglin c have long-range effects: evidence from molecular dynamics simulations.
|
| |
Proteins,
63,
356-372.
|
 |
|
|
|
|
 |
M.V.Petoukhov,
and
D.I.Svergun
(2005).
Global rigid body modeling of macromolecular complexes against small-angle scattering data.
|
| |
Biophys J,
89,
1237-1250.
|
 |
|
|
|
|
 |
N.Singh,
T.Jabeen,
S.Sharma,
I.Roy,
M.N.Gupta,
S.Bilgrami,
R.K.Somvanshi,
S.Dey,
M.Perbandt,
C.Betzel,
A.Srinivasan,
and
T.P.Singh
(2005).
Detection of native peptides as potent inhibitors of enzymes. Crystal structure of the complex formed between treated bovine alpha-chymotrypsin and an autocatalytically produced fragment, IIe-Val-Asn-Gly-Glu-Glu-Ala-Val-Pro-Gly-Ser-Trp-Pro-Trp, at 2.2 angstroms resolution.
|
| |
FEBS J,
272,
562-572.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
T.S.Zamolodchikova,
E.V.Smirnova,
A.N.Andrianov,
I.V.Kashparov,
O.D.Kotsareva,
E.A.Sokolova,
K.B.Ignatov,
and
A.D.Pemberton
(2005).
Cloning and molecular modeling of duodenase with respect to evolution of substrate specificity within mammalian serine proteases that have lost a conserved active-site disulfide bond.
|
| |
Biochemistry (Mosc),
70,
672-684.
|
 |
|
|
|
|
 |
C.Yan,
V.Honavar,
and
D.Dobbs
(2004).
Identification of interface residues in protease-inhibitor and antigen-antibody complexes: a support vector machine approach.
|
| |
Neural Comput Appl,
13,
123-129.
|
 |
|
|
|
|
 |
I.Botos,
E.E.Melnikov,
S.Cherry,
J.E.Tropea,
A.G.Khalatova,
F.Rasulova,
Z.Dauter,
M.R.Maurizi,
T.V.Rotanova,
A.Wlodawer,
and
A.Gustchina
(2004).
The catalytic domain of Escherichia coli Lon protease has a unique fold and a Ser-Lys dyad in the active site.
|
| |
J Biol Chem,
279,
8140-8148.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
T.Z.Sen,
A.Kloczkowski,
R.L.Jernigan,
C.Yan,
V.Honavar,
K.M.Ho,
C.Z.Wang,
Y.Ihm,
H.Cao,
X.Gu,
and
D.Dobbs
(2004).
Predicting binding sites of hydrolase-inhibitor complexes by combining several methods.
|
| |
BMC Bioinformatics,
5,
205.
|
 |
|
|
|
|
 |
W.Y.Lu,
M.A.Starovasnik,
J.J.Dwyer,
A.A.Kossiakoff,
S.B.Kent,
and
W.Lu
(2000).
Deciphering the role of the electrostatic interactions involving Gly70 in eglin C by total chemical protein synthesis.
|
| |
Biochemistry,
39,
3575-3584.
|
 |
|
|
|
|
 |
J.K.Dattagupta,
A.Podder,
C.Chakrabarti,
U.Sen,
D.Mukhopadhyay,
S.K.Dutta,
and
M.Singh
(1999).
Refined crystal structure (2.3 A) of a double-headed winged bean alpha-chymotrypsin inhibitor and location of its second reactive site.
|
| |
Proteins,
35,
321-331.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.E.Knobe,
A.Berntsdotter,
L.Shen,
J.Morser,
B.Dahlbäck,
and
B.O.Villoutreix
(1999).
Probing the activation of protein C by the thrombin-thrombomodulin complex using structural analysis, site-directed mutagenesis, and computer modeling.
|
| |
Proteins,
35,
218-234.
|
 |
|
|
|
|
 |
M.A.Qasim,
S.M.Lu,
J.Ding,
K.S.Bateman,
M.N.James,
S.Anderson,
J.Song,
J.L.Markley,
P.J.Ganz,
C.W.Saunders,
and
M.Laskowski
(1999).
Thermodynamic criterion for the conformation of P1 residues of substrates and of inhibitors in complexes with serine proteinases.
|
| |
Biochemistry,
38,
7142-7150.
|
 |
|
|
|
|
 |
W.Lu,
M.Randal,
A.Kossiakoff,
and
S.B.Kent
(1999).
Probing intermolecular backbone H-bonding in serine proteinase-protein inhibitor complexes.
|
| |
Chem Biol,
6,
419-427.
|
 |
|
|
|
|
 |
C.M.Lukacs,
H.Rubin,
and
D.W.Christianson
(1998).
Engineering an anion-binding cavity in antichymotrypsin modulates the "spring-loaded" serpin-protease interaction.
|
| |
Biochemistry,
37,
3297-3304.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
F.Martin,
N.Dimasi,
C.Volpari,
C.Perrera,
S.Di Marco,
M.Brunetti,
C.Steinkühler,
R.De Francesco,
and
M.Sollazzo
(1998).
Design of selective eglin inhibitors of HCV NS3 proteinase.
|
| |
Biochemistry,
37,
11459-11468.
|
 |
|
|
|
|
 |
J.Polanowska,
I.Krokoszynska,
H.Czapinska,
W.Watorek,
M.Dadlez,
and
J.Otlewski
(1998).
Specificity of human cathepsin G.
|
| |
Biochim Biophys Acta,
1386,
189-198.
|
 |
|
|
|
|
 |
C.Capasso,
M.Rizzi,
E.Menegatti,
P.Ascenzi,
and
M.Bolognesi
(1997).
Crystal structure of the bovine alpha-chymotrypsin:Kunitz inhibitor complex. An example of multiple protein:protein recognition sites.
|
| |
J Mol Recognit,
10,
26-35.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.A.Qasim,
P.J.Ganz,
C.W.Saunders,
K.S.Bateman,
M.N.James,
and
M.Laskowski
(1997).
Interscaffolding additivity. Association of P1 variants of eglin c and of turkey ovomucoid third domain with serine proteinases.
|
| |
Biochemistry,
36,
1598-1607.
|
 |
|
|
|
|
 |
B.F.Le Bonniec,
T.Myles,
T.Johnson,
C.G.Knight,
C.Tapparelli,
and
S.R.Stone
(1996).
Characterization of the P2' and P3' specificities of thrombin using fluorescence-quenched substrates and mapping of the subsites by mutagenesis.
|
| |
Biochemistry,
35,
7114-7122.
|
 |
|
|
|
|
 |
B.O.Villoutreix,
H.Lilja,
K.Pettersson,
T.Lövgren,
and
O.Teleman
(1996).
Structural investigation of the alpha-1-antichymotrypsin: prostate-specific antigen complex by comparative model building.
|
| |
Protein Sci,
5,
836-851.
|
 |
|
|
|
|
 |
E.S.Stavridi,
K.O'Malley,
C.M.Lukacs,
W.T.Moore,
J.D.Lambris,
D.W.Christianson,
H.Rubin,
and
B.S.Cooperman
(1996).
Structural change in alpha-chymotrypsin induced by complexation with alpha 1-antichymotrypsin as seen by enhanced sensitivity to proteolysis.
|
| |
Biochemistry,
35,
10608-10615.
|
 |
|
|
|
|
 |
J.Janin
(1995).
Elusive affinities.
|
| |
Proteins,
21,
30-39.
|
 |
|
|
|
|
 |
P.Ascenzi,
G.Amiconi,
W.Bode,
M.Bolognesi,
M.Coletta,
and
E.Menegatti
(1995).
Proteinase inhibitors from the European medicinal leech Hirudo medicinalis: structural, functional and biomedical aspects.
|
| |
Mol Aspects Med,
16,
215-313.
|
 |
|
|
|
|
 |
L.L.Beuning,
T.W.Spriggs,
and
J.T.Christeller
(1994).
Evolution of the proteinase inhibitor I family and apparent lack of hypervariability in the proteinase contact loop.
|
| |
J Mol Evol,
39,
644-654.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |